Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$8.48 - $14.97 $1.16 Million - $2.04 Million
136,600 Added 853.75%
152,600 $2.28 Million
Q3 2022

Nov 14, 2022

BUY
$6.61 - $8.72 $105,760 - $139,520
16,000 New
16,000 $132,000
Q3 2021

Nov 15, 2021

SELL
$5.12 - $6.89 $671,667 - $903,864
-131,185 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$6.21 - $7.45 $337,824 - $405,280
-54,400 Reduced 29.31%
131,185 $865,000
Q1 2021

May 17, 2021

BUY
$5.97 - $15.28 $1.03 Million - $2.64 Million
173,100 Added 1386.46%
185,585 $1.36 Million
Q4 2020

Feb 16, 2021

BUY
$5.08 - $6.68 $63,423 - $83,399
12,485 New
12,485 $72,000
Q3 2020

Nov 16, 2020

SELL
$4.16 - $6.26 $83,553 - $125,732
-20,085 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$3.47 - $9.99 $69,694 - $200,649
20,085 New
20,085 $103,000

Others Institutions Holding AVEO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About AVEO PHARMACEUTICALS, INC.


  • Ticker AVEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,676,000
  • Description
  • AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...
More about AVEO
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.